Zanidatamab Zovodotin is a monoclonal antibody conjugated commercialized by Zymeworks, with a leading Phase I program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 3 clinical trials, of which 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zanidatamab Zovodotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zanidatamab Zovodotin is expected to reach an annual total of $68 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zanidatamab Zovodotin Overview
Zanidatamab Zovodotin is under development for the treatment of HER-2 positive breast cancer, brain metastases, endometrial cancer, gastroesophageal adenocarcinoma, gynecologic cancers, non-small cell lung cancer, anal cancer, and colorectal cancer. It is being administered through intravenous route. The drug candidate is an bi-specific antibody-drug conjugate (ADC) targeting HER2. It comprises Azymetric biparatopic anti-HER2 antibody conjugated to proprietary cytotoxic payload via a cleavable linker. It is developed based on Azymetric and Zymelink technology platforms. These technologies enables the production of ADCs with target affinity, effector function and increase in circulation half life. ZW49 delivers a novel auristatin (cell-killing compound) to tumor cells by taking advantage of the enhanced antibody-HER2 internalization of zanidatamab.
Zymeworks is a clinical stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The company product pipeline includes the lead candidate Zanidatamab for the treatment of biliary tract cancers, breast cancer, gastroesophageal adenocarcinomas and colorectal cancer, Zanidatamab Zovodotin for HER2-expressing cancers, ZW191 – TOPO1i antibody drug conjugate for ovarian and gynecological cancers and ZW171 – 2+1 T-Cell for solid tumor. Zymeworks technology platform comprises Azymetric, Zymelink, Efect and Protect. It operates in the US and Canada. Zymeworks is headquartered in Vancouver, British Columbia, Canada.
The company reported revenues of (US Dollars) US$26.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 31.5% over FY2020. The operating loss of the company was US$215.6 million in FY2021, compared to an operating loss of US$187.5 million in FY2020. The net loss of the company was US$211.8 million in FY2021, compared to a net loss of US$180.6 million in FY2020. The company reported revenues of US$2.6 million for the third quarter ended September 2022, a decrease of 51.7% over the previous quarter.
For a complete picture of Zanidatamab Zovodotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.